Trial Profile

A prospective trial to evaluate the safety and efficacy of ATI-1501 in children with Clostridium difficile infection

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2017 According to an Appili Therapeutics media release, both the US Food and Drug Administration (FDA) and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501. The company will begin recruiting subjects in November 2017.
28 Apr 2016 New trial record
12 Apr 2016 According to an Appili Therapeutics media release, the company plans start clinical trials of ATI-1501 for Clostridium difficile infection in 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com